July 2020

Zimmer Biomet Enters Product Development Arrangement With Private Equity Firm

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal health care, entered into an innovative, outsourced product development arrangement with a private equity firm. 

Under the arrangement, Zimmer Biomet transferred its rights in a portfolio of development-stage products to a newly organized company (NewCo) – created, managed and funded by the private equity partner for the sole purpose of pursuing the development and regulatory approval of the products. Acting as a service provider to NewCo, Zimmer Biomet will continue to participate in the development of the products, which will be off-balance-sheet for financial and accounting purposes. As each product receives regulatory approval, Zimmer Biomet will repurchase it from NewCo for a pre-agreed price and under pre-agreed terms and conditions. The NewCo structure was launched in July 2020 and has the potential to play an important role in Zimmer Biomet’s R&D activities for many years to come.

Faegre Drinker represented Zimmer Biomet in the deal.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.